Zacks Investment Research upgraded shares of Heska (NASDAQ:HSKA) from a hold rating to a buy rating in a research report report published on Thursday. The firm currently has $101.00 price target on the medical research company’s stock.
According to Zacks, “Heska Corporation sells advanced veterinary diagnostic and specialty products. Heska’s state-of-the-art offerings include blood testing instruments and supplies, digital imaging products, software and services, data services, allergy testing and immunotherapy, and single-use offerings such as in-clinic diagnostic tests and heartworm preventive products. The Company’s core focus is on the canine and feline markets where it strives to provide high value products and unparalleled support to veterinarians. “
Separately, BidaskClub raised Heska from a hold rating to a buy rating in a research note on Wednesday, October 24th. Four research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The company currently has a consensus rating of Hold and an average target price of $106.20.
Heska (NASDAQ:HSKA) last posted its quarterly earnings data on Tuesday, November 6th. The medical research company reported $0.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.35 by $0.11. Heska had a return on equity of 11.48% and a net margin of 1.01%. The firm had revenue of $30.96 million for the quarter, compared to the consensus estimate of $31.14 million. Equities research analysts anticipate that Heska will post 1.74 earnings per share for the current year.
In related news, COO Jason A. Napolitano sold 3,000 shares of the stock in a transaction that occurred on Monday, December 3rd. The shares were sold at an average price of $104.17, for a total value of $312,510.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Kevin S. Wilson sold 1,631 shares of the stock in a transaction that occurred on Friday, November 30th. The shares were sold at an average price of $104.00, for a total transaction of $169,624.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 18,702 shares of company stock worth $1,897,809. Corporate insiders own 15.90% of the company’s stock.
Hedge funds have recently bought and sold shares of the company. SG Americas Securities LLC acquired a new position in shares of Heska in the 2nd quarter valued at $191,000. Greenwood Capital Associates LLC acquired a new position in Heska in the third quarter valued at about $210,000. Virtu Financial LLC acquired a new position in Heska in the third quarter valued at about $223,000. Paloma Partners Management Co acquired a new position in Heska in the second quarter valued at about $228,000. Finally, Macquarie Group Ltd. acquired a new position in Heska in the second quarter valued at about $234,000. 89.82% of the stock is currently owned by institutional investors.
Heska Company Profile
Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal Health segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; HT5 and HEMATRUE veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; COAG veterinary analyzers; Element i immunodiagnostic analyzers; and IV infusion pumps.
Recommended Story: What are catch-up contributions?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.